Top story
STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer. You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from future major European cancer conferences in your inbox. We’ve made it. Here’s our last newsletter from this year’s European Society for Medical Oncology meeting. But before we bust out of this convention center for the final time, a remi…
